Mineralys Therapeutics (MLYS) Income Statement (2022 - 2026)
Income Statement report data from Mar 31, 2022 to Mar 31, 2026 for Mineralys Therapeutics (MLYS).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||||
Research And Development | 24M (-0.12%) | 24M (-22.42%) | 31M (-17.84%) | 38M (+1.06%) | 38M (-15.01%) | 45M (-17.45%) | 54M (+37.48%) | 39M (+27.71%) | 31M (+29.80%) | 24M (+5.29%) | 23M (+89.39%) | 12M (-3.34%) | 12M (+57.16%) | 7.82M (+29.04%) | 6.06M (+8.21%) | 5.60M (-17.40%) | 6.78M |
Selling General And Administrative | 21M (+51.15%) | 14M (+43.39%) | 9.68M (+14.29%) | 8.47M (+28.92%) | 6.57M (-8.75%) | 7.20M (+17.65%) | 6.12M (+3.73%) | 5.90M (+27.98%) | 4.61M (+14.39%) | 4.03M (+6.90%) | 3.77M (-2.08%) | 3.85M (+45.28%) | 2.65M (+21.00%) | 2.19M (+61.03%) | 1.36M (+54.55%) | 880K (+11.39%) | 790K |
Operating Expenses | 45M (+18.44%) | 38M (-6.93%) | 41M (-12.02%) | 47M (+5.17%) | 44M (-14.14%) | 52M (-13.87%) | 60M (+33.08%) | 45M (+27.74%) | 35M (+27.61%) | 28M (+5.48%) | 26M (+66.90%) | 16M (+5.35%) | 15M (+49.25%) | 10M (+34.91%) | 7.42M (+14.51%) | 6.48M (-14.40%) | 7.57M |
Depreciation And Amortization | 10K (-75.00%) | 40K | - | - | 20K (-50.00%) | 40K | - | - | 10K | - | - | - | - | - | - | - | - |
Operating Income | |||||||||||||||||
Operating Income | -45.34M (+18.44%) | -38.28M (-6.93%) | -41.13M (-12.02%) | -46.75M (+5.17%) | -44.45M (-14.14%) | -51.77M (-13.87%) | -60.11M (+33.08%) | -45.17M (+27.74%) | -35.36M (+27.61%) | -27.71M (+5.48%) | -26.27M (+67.01%) | -15.73M (+5.29%) | -14.94M (+49.25%) | -10.01M (+34.91%) | -7.42M (+14.51%) | -6.48M (-14.40%) | -7.57M |
Ebit | -45.34M (+18.44%) | -38.28M (-6.93%) | -41.13M (-12.02%) | -46.75M (+5.17%) | -44.45M (-14.14%) | -51.77M (-13.87%) | -60.11M (+33.08%) | -45.17M (+27.74%) | -35.36M (+27.61%) | -27.71M (+5.48%) | -26.27M (+67.01%) | -15.73M (+5.29%) | -14.94M (+49.25%) | -10.01M (+34.91%) | -7.42M (+14.51%) | -6.48M (-14.40%) | -7.57M |
EBITDA | -45.33M (-1.26%) | -45.91M (+24.32%) | -36.93M (-14.65%) | -43.27M (-2.61%) | -44.43M (-25.52%) | -59.65M (+5.88%) | -56.34M (+37.38%) | -41.01M (+16.01%) | -35.35M (+1.52%) | -34.82M (+52.99%) | -22.76M (+87.48%) | -12.14M (-18.74%) | -14.94M (+64.72%) | -9.07M (+35.78%) | -6.68M (+3.09%) | -6.48M (-14.40%) | -7.57M |
Other Income / Expenses | |||||||||||||||||
Other Non Operating Income | 10K | - | - | - | - | 10K | -10.00K | - | - | - | - | 3.59M (+54.08%) | 2.33M (+38.69%) | 1.68M (+124.00%) | 750K | - | - |
Net Income | |||||||||||||||||
Net Income From Continuing Operations | -39.34M (+22.06%) | -32.23M (-12.73%) | -36.93M (-14.65%) | -43.27M (+2.51%) | -42.21M (-13.77%) | -48.95M (-13.12%) | -56.34M (+37.38%) | -41.01M (+30.15%) | -31.51M (+29.19%) | -24.39M (+7.16%) | -22.76M (+87.48%) | -12.14M (-3.73%) | -12.61M (+39.03%) | -9.07M (+35.78%) | -6.68M (+3.09%) | -6.48M (-14.40%) | -7.57M |
Net Income | -39.34M (+22.06%) | -32.23M (-12.73%) | -36.93M (-14.65%) | -43.27M (+2.51%) | -42.21M (-13.77%) | -48.95M (-13.12%) | -56.34M (+37.38%) | -41.01M (+30.15%) | -31.51M (+29.19%) | -24.39M (+7.16%) | -22.76M (+87.48%) | -12.14M (-3.73%) | -12.61M (+39.03%) | -9.07M (+35.78%) | -6.68M (+3.09%) | -6.48M (-14.40%) | -7.57M |